Burden of systemic glucocorticoid-related complications in severe asthma

References

• Krishnan JA, Davis SQ, Naureckas ET, et al. An umbrella review: corticosteroid therapy for adults with acute asthma. Am J Med 2009;122:977-91
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Owens P; Agency of Healthcare Research and Quality. Adverse drug events in U.S. hospitals 2004. Health Cost Util Proj 2007;1-12
   Google Scholar
• Hoes JN, Jacobs JWG, Verstappen SMM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009;68:1833-8
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011;33:1413-32
   PubMed Web of Science ®Google Scholar
• Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute, 2007. Available at: www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines [Last accessed 17 February 2016]
   Google Scholar
• Bel EH, Wenzel SE, Thompson P, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189-97
   PubMed Web of Science ®Google Scholar
• The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe asthma. Eur Respir J 2003;22:470-7
   PubMed Web of Science ®Google Scholar
• Heaney LG, Brightling CE, Menzies-Gow A, et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010;65:787-94
   PubMed Web of Science ®Google Scholar
• Pakhale S, Mulpuru S, Boyd M. Optimal management of severe/refractory asthma. Clin Med Insights Circ Respir Pulm Med 2011;5:37-47
   PubMedGoogle Scholar
• Ivanova JI, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012;129:1229-35
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004;125:1081-102
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Campbell JD, Ghushchyan VH, et al. Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation. J Asthma 2015;52:669-80
   PubMed Web of Science ®Google Scholar
• Dalal AA, Duh MS, Gozalo L, et al. Dose–response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm 2016;22:833-47
   PubMedGoogle Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol 2015;136:1488-95
   PubMed Web of Science ®Google Scholar
• Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology 2011;50:1982-90
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105-11
   PubMed Web of Science ®Google Scholar
• Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res 2013;65:294-8
   PubMed Web of Science ®Google Scholar
• Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002;61:32-6
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8
   PubMed Web of Science ®Google Scholar
• Sumino K, O’Brian K, Bartle B, et al. Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma. J Asthma 2014;51:306-14
   PubMed Web of Science ®Google Scholar
• Thamer M, Hernán MA, Zhang Y, et al. Prednisone, lupus activity and permanent organ damage. J Rheumatol 2009;36:560-4
   PubMed Web of Science ®Google Scholar
• Shah M, Chaudhari S, McLaughlin TP, et al. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. Clin Ther 2013;35:486-97
   PubMed Web of Science ®Google Scholar
• Consumer price index (CPI). Bureau of Labor Statistics, 2014. Available at: www.bls.gov/cpi/ [Last accessed 8 February 2015]
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Imbens G. The role of the propensity score in estimating dose–response functions. Biometrika 2000;87:706-10
   Web of Science ®Google Scholar
• Zazzali JL, Broder MS, Omachi TA, et al. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy Asthma Proc 2015;36:268-74
   PubMed Web of Science ®Google Scholar
• Gold DR, Wright R. Population disparities in asthma. Annu Rev Public Health 2005;26:89-113
   PubMed Web of Science ®Google Scholar
• Forno E, Celedon JC. Asthma and ethnic minorities: socioeconomic status and beyond. Curr Opin Allergy Clin Immunol 2009;9:154-60
   PubMed Web of Science ®Google Scholar
• O’Neil S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015;70:376-8
   PubMed Web of Science ®Google Scholar
• Inhaled steroids approximate dose conversions for adults. Greater Rochester Independent Practice Association, 2005. Available at: gripa.org/documents/pharmacy-tidbits/steroid-inhaler-conversion-chart-12-05-pharmacy-tidbit.pdf [Last accessed 30 September 2015]
   Google Scholar
• Szefler S. Equivalence between oral prednisone and fluticasone in terms of systemic activity. Am Acad Allergy Asthma Immunol, 2013. Available at: www.aaaai.org/ask-the-expert/equivalence-oral-prednisone-and-fluticason.aspx [Last accessed 30 September 2015]
   Google Scholar
• Toogood JH, Baskerville J, Jennings B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989;84:688-700
   PubMed Web of Science ®Google Scholar
• Global strategy for asthma management and prevention. Global Initative for Asthma, 2014. Available at: www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf [Last accessed 10 February 2015]
   Google Scholar